Inmaculada Alés

Adjuvant <i>nab</i> -Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial

Margaret A. Tempero, Uwe Pelzer, Eileen M. O’Reilly et al. · Journal of Clinical Oncology · 2022 · 132 citations · Full text

Medicine, Oncology, Pharmacology +13

Phase II study of trastuzumab and cisplatin as first-line therapy in patients with HER2-positive advanced gastric or gastroesophageal junction cancer

Cristina Grávalos, Carlos Gómez-Martín, Fernando Rivera et al. · Clinical & Translational Oncology · 2011 · 80 citations

Medicine, Oncology, Pharmacotherapy +17

Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trial

Philippe Merle, Jean‐Frédéric Blanc, Jean–Marc Phelip et al. · ˜The œLancet. Gastroenterology & hepatology · 2019 · 61 citations · Full text

Pharmacy, Oncology, Pharmacology +17

Tumor Treating Fields With Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal Phase III PANOVA-3 Study

Hani M. Babiker, Vincent J. Picozzi, Sreenivasa R Chandana et al. · Journal of Clinical Oncology · 2025 · 38 citations · Full text

Medicine, Oncology, Pharmacology +9

<i>Nab</i> -Paclitaxel plus Gemcitabine and FOLFOX in Metastatic Pancreatic Cancer

Alfredo Carrato, Roberto Pazo-Cid, Teresa Macarulla et al. · NEJM Evidence · 2024 · 22 citations · Full text

Medicine, Oncology, Pharmacology +17